Proceeds to support advancement of extremely accurate and precise biomarker
for improved management of theranostic treatments.
MADISON, Wis.—Voximetry is an early commercial stage medical software and services company with unique technology to enable personalized Radiopharmaceutical Therapy (RPT) treatments for prostate and other cancer patients. The round was company led, with participation from Wisconsin Alumni Research Foundation (WARF). Voximetry began as a University of Wisconsin – Madison start-up.
According to Voximetry CEO, Dr. Sue Wallace, “We are grateful to the investors who believe in the competence of our team and the differentiation of our technology. We plan to use these funds to fuel commercial growth and establish Torch® Dose Assessment as an accurate and precise imaging biomarker.”
The field of RPT is expanding rapidly in the U.S. with procedure volumes increasing in multiple specialty areas including Nuclear Medicine, Radiation Oncology, and Interventional Radiology departments.
In the U.S. alone, over 350,000 patients per year are indicated for FDA approved theranostic treatments including Prostate, Lymphoma, Thyroid, Liver, and Neuroendocrine tumors. Without a way to measure how a patient’s individual body will react to these therapies, physicians are left using one-size-fits-all dosing strategies. Torch Dose Assessment provides the quantitative imaging biomarker needed to enable personalized treatments and better outcomes.
“Quantitation is key,” said Dr. Joe Grudzinski, Co-Founder and Chief Innovation Officer at Voximetry. “Clinicians have needed a quantitative dosimetry assessment they could trust to better personalize care for a long time. Now we have the product, and the next step is to maximize patient access to this automated technology and personalized treatments. These late-stage patients don’t have a lot of time and we’re working to meet them where they are being treated.”
Voximetry sells subscription software as a service for measuring dosimetry imaging biomarkers. In addition, the company offers professional services to analyze patient data in-house and deliver comprehensive clinical dose assessments with imaging biomarker information directly to clinicians and drug developers.
Torch design and development was supported by the National Cancer Institute of the National Institutes of Health under Award Number R43CA221491. The product is solely the responsibility of Voximetry and does not represent official views of the National Institutes of Health.
Torch design and development was supported by grants from the University of Wisconsin-System SBIR Advance Matching Grant Fund through its partnership with the Wisconsin Economic Development Corporation.
About Voximetry: Based in Madison, Wisconsin, Voximetry is a is Healthtech software and services company specializing in commercialization of complex algorithms on high-speed Graphic Processing Units (GPUs). Currently focused on radiation transport science and voxel-level dosimetry, Voximetry is pioneering patient-specific radiopharmaceutical treatment planning (RPT) in advanced stage cancer patients.